PUBLISHER: Grand View Research | PRODUCT CODE: 1842051
PUBLISHER: Grand View Research | PRODUCT CODE: 1842051
The global high and ultra-high-field nuclear magnetic resonance spectroscopy market size was estimated at USD 561.67 million in 2024 and is projected to reach USD 1,033.67 million by 2035, growing at a CAGR of 5.65% from 2025 to 2035. Market growth can be attributed to the increasing funding & investment initiatives for nuclear magnetic resonance (NMR) spectroscopy in biomedical research, the rising need for affordable generic medicines, the growing scope of NMR spectroscopy in non-healthcare sectors, aided by the rising adoption of the technique in medical diagnosis.
Nuclear Magnetic Resonance (NMR) spectroscopy is an effective method for assessing crystalline and amorphous pharmaceuticals in both drugs and their finished products. The development of generic medicines is expected to increase demand for NMR, as it supports essential processes in the pharmaceutical industry, such as drug substance characterization, determination of crystalline structures, and monitoring of form conversion during active pharmaceutical ingredient (API) scale-up. Solid-state NMR (SSNMR) is vital for investigating multiple crystalline forms in APIs and drug products. With drug development activity continuing to grow, the requirement for NMR spectroscopy is set to rise significantly, supported by universities, product developers, and pharmaceutical service providers.
NMR spectroscopy is also expanding its role in diagnostics and biomedical research. The technique allows the study of peptides, proteins, nucleic acids, and amino acids, providing insights into their structure, dynamics, and molecular interactions. As research in the biomedical field increases, the use of NMR is expected to accelerate. According to the World Health Organization (WHO), the number of funders and their contributions to biomedical research have been growing steadily since 2012. In 2020, about 74,702 grants were awarded, with the U.S. National Institutes of Health (NIH) providing the largest share. This steady growth in funding highlights the importance of NMR as a widely used tool in biomedical science.
NMR has gained attention in medical diagnosis due to its nondestructive, noninvasive nature and simple sample preparation. These qualities make it highly effective for metabolomics studies. Research has explored its use in diagnosing Parkinson's disease, cancer, infectious conditions, and psychiatric disorders. Companies and academic institutions are actively developing metabolomics-based diagnostic tools using NMR. For example, in January 2022, the University of Oxford developed a blood test based on NMR metabolomics to detect various cancers. Similarly, Lifespin, a metabolomics testing company, reported in 2021 that it had created NMR-based metabolic profiles for about 130,000 individuals across multiple disease cohorts, providing a foundation for developing diagnostic applications. These initiatives show the growing focus on NMR in clinical research and diagnostics.
Technological advancements are now complementing this rising adoption. In April 2025, Bruker Corporation announced the world's first 1.3 GHz high-resolution NMR spectrometer at the Joint ENC-ISMAR Conference. Installed at its ultra-high field facility in Fallanden, Switzerland, the spectrometer is based on a hybrid low-temperature (LTS) and high-temperature (HTS) superconducting magnet architecture. Delivering a field strength of 30.5 Tesla with a novel ReBCO HTS insert, the 1.3 GHz instrument provides unprecedented resolution and sensitivity while maintaining the same footprint and cryogen efficiency as Bruker's 1.2 GHz systems.
Application testing confirmed the versatility of the platform, with high-resolution spectra obtained for both liquid and solid-state samples across multiple probe configurations, including advanced ultra-fast spinning MAS probes. The stronger magnetic field offers unique benefits for biomolecular research, particularly in studying carbohydrates, glycoproteins, RNA, and intrinsically disordered proteins (IDPs). Direct ^13C and ^15N detection of IDPs demonstrated clear sensitivity gains, opening new approaches for studying molecular dynamics and function at atomic resolution. In solid-state applications, the enhanced field narrowed spectral lines for quadrupolar nuclei and improved chemical shift tensor measurements, providing powerful capabilities for complex materials research.
"Reaching 1.3 GHz is yet another milestone in Bruker's commitment to innovation," said the President of the Bruker BioSpin Group. "Our GHz-class NMRs enable researchers to advance their understanding of complex biomolecular systems while supporting major breakthroughs in materials science, particularly for compounds with quadrupolar and low-gamma nuclei."
Early adopters confirmed the impact of the technology. The RIKEN Yokohama Institute in Japan reported a remarkable gain in resolution and sensitivity for protein and nucleic acid samples. At the same time, CEMHTI-CNRS Orleans, France, highlighted dramatic improvements in resolving atomic environments in materials.
The broad use of NMR in pharmaceuticals, the steady rise in biomedical research funding, the growing interest in metabolomics-based diagnostics, and technological milestones such as Bruker's 1.3 GHz spectrometer are reshaping the field. NMR spectroscopy is now firmly positioned as a cornerstone technology driving life sciences and materials research progress.
Global High And Ultra-high-field Nuclear Magnetic Resonance Spectroscopy Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Grand View Research has segmented the global high and ultra-high-field nuclear magnetic resonance spectroscopy market report based on frequency type, application, end-use, and region: